AGÕæÈ˹ٷ½

STOCK TITAN

TruBridge Announces Second Quarter 2025 Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

MOBILE, Ala.--(BUSINESS WIRE)-- TruBridge, Inc. (NASDAQ: TBRG), a healthcare solutions company, today announced financial results for the second quarter and six months ended June 30, 2025.

Second Quarter 2025 Highlights*

All comparisons are to the quarter ended June 30, 2024, unless otherwise noted

  • Total bookings of $25.6 million compared to $23.3 million
  • Total revenue of $85.7 million compared to $85.6 million
    • Recurring revenue represented 95% of total revenue
  • Financial Health revenue of $54.3 million compared to $54.5 million
    • Financial Health revenue represented 63% of TruBridge’s total revenue
  • GAAP net income of $2.6 million compared to a net loss of $4.4 million
  • Non-GAAP net income of $7.9 million compared to $3.0 million
  • Adjusted EBITDA of $13.7 million compared to $13.4 million

*As of the third quarter of 2024, TruBridge is now reporting two segments in its financial statements representing the two business units. Financial Health represents the previous Revenue Cycle Management (RCM) segment, and Patient Care represents the previous Electronic Health Record (EHR) segment, including the patient engagement business.

Commenting on the results, Chris Fowler, chief executive officer of TruBridge, Inc., stated, “During the second quarter, we continued to make improvements on many fronts, advancing steadily towards achievement of our long-term objectives. Strong bookings, as well as improved profitability and cash flow, give us confidence in the value we provide to our clients, our position in the market, and the benefits of the work we did to improve the financial health of our business.

“Our north star is client delight, and we are implementing a strategic plan designed to bring our client satisfaction levels back to historical levels and beyond. While we have brought down the top end of our revenue outlook for the full year as a result of client attrition and the reality of signing larger, more complex deals, we are also raising our Adjusted EBITDA range to incorporate the efficiencies realized by our offshoring initiative, our refinement of resource management, and cost optimization. We remain confident that the steps we are taking today to refine and optimize our approach will set us up for success in the quarters and years ahead as we work to deliver exceptional experiences to the communities we serve,� added Fowler.

Financial Guidance

For the third quarter of 2025, TruBridge expects to generate:

  • Total revenue of $85 million to $87 million
  • Adjusted EBITDA of $14 million to $16 million

For the full year 2025, TruBridge expects to generate:

  • Total revenue of $345 million to $350 million; revised from $345 million to $360 million
  • Adjusted EBITDA of $62 million to $67 million; revised from $60 million to $66 million

Conference Call

TruBridge will hold a conference call and live webcast to discuss second quarter 2025 results on Friday, August 8, 2025, at 7:30 a.m. Central time/8:30 a.m. Eastern time. To access this interactive teleconference, dial (877) 407-0890 and request connection to the TruBridge earnings conference call. A 30-day online replay will be available approximately one hour following the conclusion of the live webcast. To listen to the live webcast or access the replay, visit the Company’s investor relations website,

About TruBridge

TruBridge proudly supports rural and community hospitals and providers in their efforts to stay strong, independent, and deeply rooted in the communities they serve. Backed by more than 45 years of healthcare experience and trusted by over 1,500 clients nationwide, we offer a mix of technology, services, and strategic expertise � including revenue cycle management, electronic health records (EHR) and analytics � all designed singularly for the realities of rural and community healthcare. With a steadfast commitment to keeping care local, TruBridge helps hospitals flourish as the economic heart of their communities, delivering high-quality, personal care close to home. For more information, visit .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor� provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified generally by the use of forward-looking terminology and words such as “expects,� “anticipates,� “estimates,� “believes,� “predicts,� “intends,� “plans,� “potential,� “may,� “continue,� “should,� “will� and words of comparable meaning. Without limiting the generality of the preceding statement, all statements in this press release relating to the Company’s future financial and operational results are forward-looking statements. We caution investors that any such forward-looking statements are only predictions and are not guarantees of future performance. Certain risks, uncertainties and other factors may cause actual results to differ materially from those projected in the forward-looking statements. Such factors may include: saturation of our target market and hospital consolidations; unfavorable economic or market conditions that may cause a decline in spending for information technology and services; significant legislative and regulatory uncertainty in the healthcare industry; exposure to liability for failure to comply with regulatory requirements; transition to a subscription based recurring revenue model and modernization of our technology; competition with companies that have greater financial, technical and marketing resources than we have; potential future acquisitions that may be expensive, time consuming, and subject to other inherent risks; our ability to attract and retain qualified personnel in a global workforce; disruption from periodic restructuring of our sales force; slower than anticipated development of the market for Financial Health services; potential inability to properly manage growth in new markets we may enter; potential failure to effectively implement a new enterprise resource planning software solution; exposure to numerous and often conflicting laws, regulations, policies, standards or other requirements through our domestic and international business activities; potential litigation against us and investigations; our use of offshore third-party resources; competitive and litigation risk related to the use of artificial intelligence; potential failure to develop new products or enhance current products that keep pace with market demands; failure of our products to provide accurate and timely information for clinical decision-making; breaches of security and viruses in our systems resulting in customer claims against us and harm to our reputation; failure to maintain customer satisfaction through new product releases free of undetected errors or problems; failure to convince customers to migrate to current or future releases of our products; failure to maintain our margins and service rates; increase in the percentage of total revenues represented by service revenues, which have lower gross margins; exposure to liability in the event we provide inaccurate claims data to payors; exposure to liability claims arising out of the licensing of our software and provision of services; dependence on licenses of rights, products and services from third parties; failure to protect our intellectual property rights; exposure to significant license fees or damages for intellectual property infringement; interruptions in our power supply and/or telecommunications capabilities; potential inability to secure additional financing on favorable terms to meet our future capital needs; our substantial indebtedness, and our ability to incur additional indebtedness in the future; pressures on cash flow to service our outstanding debt; restrictive terms of our credit agreement on our current and future operations; changes in and interpretations of financial accounting matters that govern the measurement of our performance; significant charges to earnings if our goodwill or intangible assets become impaired; fluctuations in quarterly financial performance due to various factors; volatility in our stock price; failure to maintain effective internal control over financial reporting; inherent limitations in our internal control over financial reporting; vulnerability to significant damage from natural disasters; market risks related to interest rate changes; potential material adverse effects due to macroeconomic conditions; we do not anticipate paying dividends on our common stock; actions of activist stockholders against us; and other risk factors described from time to time in our public releases and reports filed with the Securities and Exchange Commission. We also caution investors that the forward-looking information described herein represents our outlook only as of this date, and we undertake no obligation to update or revise any forward-looking statements to reflect events or developments after the date of this press release.

TruBridge, Inc.

Condensed Consolidated Statements of Operations

(In '000s, except per share data)

(Unaudited)

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Three Months Ended June 30,

Ìý

Six Months Ended June 30,

Ìý

2025

Ìý

2024 *

Ìý

2025

Ìý

2024 *

Revenues
Financial Health

$

54,284

$

54,509

$

110,417

$

107,948

Patient Care

Ìý

31,445

Ìý

Ìý

31,091

Ìý

Ìý

62,520

Ìý

Ìý

61,769

Ìý

Total revenues

Ìý

85,729

Ìý

Ìý

85,600

Ìý

Ìý

172,937

Ìý

Ìý

169,717

Ìý

Ìý
Expenses
Costs of revenue (exclusive of amortization and depreciation)
Financial Health

Ìý

29,308

Ìý

Ìý

30,269

Ìý

Ìý

56,499

Ìý

Ìý

59,866

Ìý

Patient Care

Ìý

11,962

Ìý

Ìý

13,073

Ìý

Ìý

24,284

Ìý

Ìý

25,237

Ìý

Total costs of revenue (exclusive of amortization and depreciation)

Ìý

41,270

Ìý

Ìý

43,342

Ìý

Ìý

80,783

Ìý

Ìý

85,103

Ìý

Product development

Ìý

8,113

Ìý

Ìý

8,207

Ìý

Ìý

16,360

Ìý

Ìý

18,894

Ìý

Sales and marketing

Ìý

8,041

Ìý

Ìý

7,815

Ìý

Ìý

13,450

Ìý

Ìý

14,408

Ìý

General and administrative

Ìý

18,076

Ìý

Ìý

18,878

Ìý

Ìý

37,540

Ìý

Ìý

38,274

Ìý

Amortization

Ìý

6,290

Ìý

Ìý

9,107

Ìý

Ìý

12,414

Ìý

Ìý

14,975

Ìý

Depreciation

Ìý

312

Ìý

Ìý

400

Ìý

Ìý

603

Ìý

Ìý

800

Ìý

Total expenses

Ìý

82,102

Ìý

Ìý

87,749

Ìý

Ìý

161,150

Ìý

Ìý

172,454

Ìý

Ìý
Operating income (loss)

Ìý

3,627

Ìý

Ìý

(2,149

)

Ìý

11,787

Ìý

Ìý

(2,737

)

Ìý
Other income (expense):
Interest expense

Ìý

(3,065

)

Ìý

(4,242

)

Ìý

(6,447

)

Ìý

(8,315

)

Other income

Ìý

136

Ìý

Ìý

91

Ìý

Ìý

280

Ìý

Ìý

1,514

Ìý

Total other expense

Ìý

(2,929

)

Ìý

(4,151

)

Ìý

(6,167

)

Ìý

(6,801

)

Ìý
Income (loss) before taxes

Ìý

698

Ìý

Ìý

(6,300

)

Ìý

5,620

Ìý

Ìý

(9,538

)

Ìý
Provision for (benefit from) income taxes

Ìý

(1,882

)

Ìý

(1,912

)

Ìý

2,581

Ìý

Ìý

(3,296

)

Ìý
Net income (loss)

$

2,580

Ìý

$

(4,388

)

$

3,039

Ìý

$

(6,242

)

Ìý
Net income (loss) per common share—basic

$

0.17

Ìý

$

(0.29

)

$

0.20

Ìý

$

0.42

Ìý

Net income (loss) per common share—diluted

$

0.17

Ìý

$

(0.29

)

$

0.20

Ìý

$

0.42

Ìý

Ìý
Weighted average shares outstanding used in per common share computations:
Basic

Ìý

14,522

Ìý

Ìý

14,313

Ìý

Ìý

14,446

Ìý

Ìý

14,273

Ìý

Diluted

Ìý

14,522

Ìý

Ìý

14,313

Ìý

Ìý

14,446

Ìý

Ìý

14,273

Ìý

Ìý
*As described in the 2024 Annual Report, certain line items have been revised to correct an error related to the reversal of revenue from customers that was recognized improperly during 2023. These revisions increased revenue for the three and six months ended June 30, 2024 by $0.9 million and $1.7 million, respectively. These revisions had no cash flow consequences.

TruBridge, Inc.

Condensed Consolidated Balance Sheets

(In '000s, except per share data)

Ìý

June 30, 2025
(Unaudited)

December 31,
2024

Assets
Current assets
Cash and cash equivalents

$

12,279

Ìý

$

12,324

Ìý

Accounts receivable, net of allowance for expected credit losses of $5,208 and $5,861

Ìý

56,432

Ìý

Ìý

53,753

Ìý

Current portion of financing receivables, net of allowance for expected credit losses of $560 and $417

Ìý

2,727

Ìý

Ìý

4,663

Ìý

Inventories

Ìý

444

Ìý

Ìý

767

Ìý

Prepaid income taxes

Ìý

3,459

Ìý

Ìý

2,886

Ìý

Prepaid expenses and other current assets

Ìý

14,473

Ìý

Ìý

15,275

Ìý

Assets held for sale

Ìý

445

Ìý

Ìý

606

Ìý

Total current assets

Ìý

90,259

Ìý

Ìý

90,274

Ìý

Ìý
Property & equipment, net

Ìý

2,559

Ìý

Ìý

2,294

Ìý

Software development costs, net

Ìý

43,317

Ìý

Ìý

41,474

Ìý

Operating lease right-of-use assets

Ìý

2,617

Ìý

Ìý

3,092

Ìý

Financing receivables, less current portion, less allowance for expected credit losses of $258 and $21

Ìý

22

Ìý

Ìý

232

Ìý

Other assets, less current portion

Ìý

8,196

Ìý

Ìý

7,786

Ìý

Intangible assets, net

Ìý

70,608

Ìý

Ìý

76,707

Ìý

Goodwill

Ìý

172,573

Ìý

Ìý

172,573

Ìý

Total assets

$

390,151

Ìý

$

394,432

Ìý

Ìý
Liabilities & Stockholders' Equity
Current liabilities
Accounts payable

$

19,672

Ìý

$

15,040

Ìý

Current portion of long-term debt

Ìý

2,980

Ìý

Ìý

2,980

Ìý

Deferred revenue

Ìý

9,368

Ìý

Ìý

10,653

Ìý

Accrued vacation

Ìý

5,235

Ìý

Ìý

4,770

Ìý

Income taxes payable

Ìý

623

Ìý

Ìý

3,538

Ìý

Other accrued liabilities

Ìý

12,302

Ìý

Ìý

15,994

Ìý

Total current liabilities

Ìý

50,180

Ìý

Ìý

52,975

Ìý

Ìý
Long-term debt, less current portion

Ìý

163,108

Ìý

Ìý

168,598

Ìý

Operating lease liabilities, less current portion

Ìý

1,827

Ìý

Ìý

2,293

Ìý

Deferred tax liabilities

Ìý

1,863

Ìý

Ìý

1,871

Ìý

Total liabilities

Ìý

216,978

Ìý

Ìý

225,737

Ìý

Ìý
Stockholders' Equity
Common stock, $0.001 par value; 30,000 shares authorized; 15,700 and 15,522 shares issued

Ìý

15

Ìý

Ìý

15

Ìý

Additional paid-in capital

Ìý

204,376

Ìý

Ìý

201,066

Ìý

Retained deficit

Ìý

(11,913

)

Ìý

(14,952

)

Accumulated other comprehensive income

Ìý

27

Ìý

Ìý

45

Ìý

Treasury stock, 685 and 619 shares

Ìý

(19,332

)

Ìý

(17,479

)

Total stockholders' equity

Ìý

173,173

Ìý

Ìý

168,695

Ìý

Ìý
Total liabilities and stockholders' equity

$

390,151

Ìý

$

394,432

Ìý

TruBridge, Inc.

Condensed Consolidated Statements of Cash Flows

(In '000s)

(Unaudited)

Ìý

Ìý

Ìý

Ìý

Ìý

Six Months Ended June 30,

Ìý

2025

Ìý

2024 *

Operating activities:
Net income (loss)

$

3,039

Ìý

$

(6,242

)

Adjustments to net income (loss):
Provision for credit losses

Ìý

1,609

Ìý

Ìý

358

Ìý

Deferred taxes

Ìý

(7

)

Ìý

(5,224

)

Stock-based compensation

Ìý

3,310

Ìý

Ìý

2,300

Ìý

Depreciation

Ìý

603

Ìý

Ìý

800

Ìý

Gain on sale of business

Ìý

(53

)

Ìý

(1,250

)

Amortization of acquisition-related intangibles

Ìý

6,098

Ìý

Ìý

6,253

Ìý

Amortization of software development costs

Ìý

6,316

Ìý

Ìý

8,722

Ìý

Amortization of deferred finance costs

Ìý

259

Ìý

Ìý

213

Ìý

Non-cash operating lease costs

Ìý

537

Ìý

Ìý

897

Ìý

Gain on disposal of property and equipment

Ìý

(120

)

Ìý

-

Ìý

Changes in operating assets and liabilities:
Accounts receivable

Ìý

(3,967

)

Ìý

(1,085

)

Financing receivables

Ìý

1,825

Ìý

Ìý

506

Ìý

Inventories

Ìý

323

Ìý

Ìý

(318

)

Prepaid expenses and other assets

Ìý

(1,827

)

Ìý

1,502

Ìý

Accounts payable

Ìý

5,082

Ìý

Ìý

5,750

Ìý

Deferred revenue

Ìý

(1,284

)

Ìý

1,769

Ìý

Operating lease liabilities

Ìý

(548

)

Ìý

(583

)

Other liabilities

Ìý

(3,191

)

Ìý

(2,375

)

Income taxes, net

Ìý

(3,487

)

Ìý

(263

)

Net cash provided by operating activities

Ìý

14,517

Ìý

Ìý

11,730

Ìý

Ìý
Investing activities:
Purchase of business, net of cash acquired

Ìý

-

Ìý

Ìý

(664

)

Sale of business, net of cash and cash equivalent sold

Ìý

2,102

Ìý

Ìý

21,410

Ìý

Investment in software development

Ìý

(8,159

)

Ìý

(9,324

)

Purchases of property and equipment

Ìý

(902

)

Ìý

(306

)

Net cash (used in) provided by investing activities

Ìý

(6,959

)

Ìý

11,116

Ìý

Ìý
Financing activities:
Payments of long-term debt principal

Ìý

(1,750

)

Ìý

(5,750

)

Proceeds from revolving line of credit

Ìý

15,368

Ìý

Ìý

21,072

Ìý

Payments of revolving line of credit

Ìý

(19,368

)

Ìý

(33,379

)

Debt issuance cost

Ìý

-

Ìý

Ìý

(529

)

Treasury stock purchases

Ìý

(1,853

)

Ìý

(358

)

Net cash used in financing activities

Ìý

(7,603

)

Ìý

(18,944

)

Ìý
(Decrease) Increase in cash and cash equivalents

Ìý

(45

)

Ìý

3,902

Ìý

Ìý
Change in cash and cash equivalents included in assets sold

Ìý

-

Ìý

Ìý

(41

)

Cash and cash equivalents, beginning of period

Ìý

12,324

Ìý

Ìý

3,848

Ìý

Cash and cash equivalents, end of period

$

12,279

Ìý

$

7,709

Ìý

Ìý
*As described in the 2024 Annual Report, certain line items have been revised to correct an error related to the reversal of revenue from customers that was recognized improperly during 2023. These revisions increased revenue for the six months ended June 30, 2024 by $1.7 million. These revisions had no cash flow consequences.

TruBridge, Inc.

Consolidated Bookings

(In '000s)

(Unaudited) (Non-GAAP)

Ìý

Three Months Ended June 30,

Six Months Ended June 30,

In '000s

Ìý

2025

Ìý

Ìý

2024

Ìý

Ìý

2025

Ìý

Ìý

2024

Ìý

Financial Health(1)

$

13,705

$

13,458

$

26,485

$

27,849

Patient Care(2)

Ìý

11,908

Ìý

Ìý

9,832

Ìý

Ìý

21,109

Ìý

Ìý

19,010

Ìý

Ìý
Total Bookings

$

25,613

Ìý

$

23,290

Ìý

$

47,594

Ìý

$

46,859

Ìý

Ìý

(1)

Generally calculated as the annual contract value

(2)

Generally calculated as the total contract value for system sales and SaaS, and annual contract value for maintenance and support
Ìý
Ìý
Annual Contract Value
Effective January 2025, the Company will be providing bookings on an Annual Contract Value (“ACV�) basis in addition to the reported bookings amounts, which has historically represented a mix of ACV and Total Contract Value (“TCV�) for Patient Care. This new methodology of reporting total bookings at ACV represents the newly contracted revenue that is expected to be recognized over a twelve-month period. Over the course of 2025, the Company will be providing total bookings under both methodologies for year over year comparability before fully transitioning to ACV in 2026.

The below table represents bookings at the ACV methodology for the three and six months ended June 30, 2025:
Ìý

Three Months
Ended June 30,

Six Months
Ended June 30,

In '000s

Ìý

2025

Ìý

Ìý

2025

Ìý

Financial Health

$

13,705

Ìý

$

26,485

Ìý

Patient Care

Ìý

5,921

Ìý

Ìý

10,480

Ìý

Ìý
Total Bookings (ACV)

$

19,626

Ìý

$

36,965

Ìý

TruBridge, Inc.

Bookings Composition

(In '000s, except per share data)

(Unaudited)

Ìý

Three Months Ended June 30,

Six Months Ended June 30,

In '000s

Ìý

2025

Ìý

Ìý

2024

Ìý

Ìý

2025

Ìý

Ìý

2024

Ìý

Financial Health
Net new(1)

$

5,067

$

6,453

$

11,529

$

15,446

Cross-sell(1)

Ìý

8,638

Ìý

Ìý

7,004

Ìý

Ìý

14,956

Ìý

Ìý

12,402

Ìý

Patient Care
Non-subscription sales(2)

Ìý

2,730

Ìý

Ìý

4,084

Ìý

Ìý

5,332

Ìý

Ìý

7,534

Ìý

Subscription revenue(3)

Ìý

9,178

Ìý

Ìý

5,749

Ìý

Ìý

15,777

Ìý

Ìý

11,477

Ìý

Ìý
Total Bookings

$

25,613

Ìý

$

23,290

Ìý

$

47,594

Ìý

$

46,859

Ìý

Ìý

(1)

“Net new� represents bookings from outside the Company’s core client base, and “Cross-sell� represents bookings from existing customers. In each case, such bookings are generally comprised of recurring revenues to be recognized ratably over a one-year period and an average timeframe for bookings-to-revenue conversion of four to six months following contract execution.

Ìý

(2)

Represents nonrecurring revenues that generally exhibit a timeframe for bookings-to-revenue conversion of five to six months following contract execution.

Ìý

(3)

Represents recurring revenues to be recognized on a monthly basis over a weighted-average contract period of five years, with a start date in the next 12 months and an average timeframe for commencement of bookings-to-revenue conversion of five to six months following contract execution.
Ìý
Ìý
Annual Contract Value
Effective January 2025, the Company will be providing bookings on an Annual Contract Value (“ACV�) basis in addition to the reported bookings amounts, which has historically represented a mix of ACV and Total Contract Value (“TCV�) for Patient Care. This new methodology of reporting total bookings at ACV represents the newly contracted revenue that is expected to be recognized over a twelve-month period. Over the course of 2025, the Company will be providing total bookings under both methodologies for year over year comparability before fully transitioning to ACV in 2026.

The below table represents bookings at the ACV methodology for the three and six months ended June 30, 2025:
Ìý

Three Months
Ended June 30,

Six Months
Ended June 30,

In '000s

Ìý

2025

Ìý

Ìý

2025

Ìý

Financial Health
Net new(1)

$

5,067

Ìý

$

11,529

Ìý

Cross-sell(1)

Ìý

8,638

Ìý

Ìý

14,956

Ìý

Patient Care
Non-subscription sales(2)

Ìý

2,730

Ìý

Ìý

5,332

Ìý

Subscription revenue(3)

Ìý

3,191

Ìý

Ìý

5,148

Ìý

Ìý
Total Bookings (ACV)

$

19,626

Ìý

$

36,965

Ìý

TruBridge, Inc.

Adjusted EBITDA - by Segment

(In '000s)

(Unaudited) (Non-GAAP)

Ìý

Three Months Ended June 30,

Ìý

Six Months Ended June 30,

In '000s

2025

2024 *

Ìý

2025

2024 *

Financial Health

$

7,092

$

8,209

$

18,373

$

15,006

Patient Care

Ìý

6,651

Ìý

$

5,235

Ìý

Ìý

13,601

Ìý

Ìý

8,762

Ìý

Ìý
Total Adjusted EBITDA

$

13,743

Ìý

$

13,444

Ìý

$

31,974

Ìý

$

23,768

Ìý

Ìý
*As described in the 2024 Annual Report, certain line items have been revised to correct an error related to the reversal of revenue from customers that was recognized improperly during 2023. These revisions increased revenue for the three and six months ended June 30, 2024 by $0.9 million and $1.7 million, respectively. These revisions had no cash flow consequences.

TruBridge, Inc.

Reconciliation of Non-GAAP Financial Measures

(In '000s)

(Unaudited)

Ìý

Three Months Ended June 30,

Ìý

Six Months Ended June 30,

Adjusted EBITDA:

2025

Ìý

2024 *

Ìý

2025

Ìý

2024 *

Total Adjusted EBITDA

$

13,743

Ìý

$

13,444

Ìý

$

31,974

Ìý

$

23,768

Ìý

Adjusted EBITDA Margin

Ìý

16.0

%

Ìý

15.7

%

Ìý

18.5

%

Ìý

14.0

%

Ìý
Ìý
Depreciation expense

Ìý

312

Ìý

Ìý

400

Ìý

Ìý

603

Ìý

Ìý

800

Ìý

Amortization of software development costs

Ìý

3,245

Ìý

Ìý

5,980

Ìý

Ìý

6,316

Ìý

Ìý

8,722

Ìý

Amortization of acquisition-related intangibles

Ìý

3,046

Ìý

Ìý

3,126

Ìý

Ìý

6,098

Ìý

Ìý

6,253

Ìý

Stock-based compensation

Ìý

2,097

Ìý

Ìý

1,501

Ìý

Ìý

3,310

Ìý

Ìý

2,300

Ìý

Severance and other nonrecurring charges

Ìý

1,416

Ìý

Ìý

4,586

Ìý

Ìý

3,860

Ìý

Ìý

8,430

Ìý

Interest expense and other income

Ìý

2,929

Ìý

Ìý

4,151

Ìý

Ìý

6,340

Ìý

Ìý

8,051

Ìý

Gain on disposal of property and equipment

Ìý

-

Ìý

Ìý

-

Ìý

Ìý

(120

)

Ìý

-

Ìý

Gain on sale of AHT

Ìý

-

Ìý

Ìý

-

Ìý

Ìý

(53

)

Ìý

(1,250

)

Income (loss) before taxes, as reported

Ìý

698

Ìý

Ìý

(6,300

)

Ìý

5,620

Ìý

Ìý

(9,538

)

Provision for (benefit from) income taxes

Ìý

(1,882

)

Ìý

(1,912

)

Ìý

2,581

Ìý

Ìý

(3,296

)

Net income (loss), as reported

$

2,580

Ìý

$

(4,388

)

$

3,039

Ìý

$

(6,242

)

Net income (loss) margin

Ìý

3.0

%

Ìý

(5.1

%)

Ìý

1.8

%

Ìý

(3.7

%)

Ìý
Ìý
*As described in the 2024 Annual Report, certain line items have been revised to correct an error related to the reversal of revenue from customers that was recognized improperly during 2023. These revisions increased revenue for the three and six months ended June 30, 2024 by $0.9 million and $1.7 million, respectively. These revisions had no cash flow consequences.

TruBridge, Inc.

Reconciliation of Non-GAAP Financial Measures

(In '000s, except per share data)

(Unaudited)

Ìý

Three Months Ended June 30,

Ìý

Six Months Ended June 30,

Non-GAAP Net Income and Non-GAAP EPS:

2025

Ìý

2024 *

Ìý

2025

Ìý

2024 *

Net income (loss), as reported

$

2,580

Ìý

$

(4,388

)

$

3,039

Ìý

$

(6,242

)

Ìý
Pre-tax adjustments for Non-GAAP EPS:
Amortization of acquisition-related intangible assets

Ìý

3,046

Ìý

Ìý

3,126

Ìý

Ìý

6,098

Ìý

Ìý

6,253

Ìý

Stock-based compensation

Ìý

2,097

Ìý

Ìý

1,501

Ìý

Ìý

3,310

Ìý

Ìý

2,300

Ìý

Severance and other nonrecurring charges

Ìý

1,416

Ìý

Ìý

4,586

Ìý

Ìý

3,860

Ìý

Ìý

8,430

Ìý

Non-cash interest expense

Ìý

130

Ìý

Ìý

107

Ìý

Ìý

260

Ìý

Ìý

213

Ìý

Gain on sale of AHT

Ìý

-

Ìý

Ìý

-

Ìý

Ìý

(53

)

Ìý

(1,250

)

After-tax adjustments for Non-GAAP EPS:
Tax-effect of pre-tax adjustments, at 21%

Ìý

(1,405

)

Ìý

(1,957

)

Ìý

(2,830

)

Ìý

(3,349

)

Tax shortfall (windfall) from stock-based compensation

Ìý

-

Ìý

Ìý

4

Ìý

Ìý

(670

)

Ìý

113

Ìý

Ìý
Non-GAAP net income

$

7,864

Ìý

$

2,979

Ìý

$

13,014

Ìý

$

6,468

Ìý

Ìý
Weighted average shares outstanding, diluted

Ìý

14,522

Ìý

Ìý

14,313

Ìý

Ìý

14,446

Ìý

Ìý

14,273

Ìý

Ìý
Non-GAAP EPS

$

0.54

Ìý

$

0.21

Ìý

$

0.90

Ìý

$

0.45

Ìý

Ìý
Ìý
*As described in the 2024 Annual Report, certain line items have been revised to correct an error related to the reversal of revenue from customers that was recognized improperly during 2023. These revisions increased revenue for the three and six months ended June 30, 2024 by $0.9 million and $1.7 million, respectively. These revisions had no cash flow consequences.
TruBridge, Inc.
Revenue Composition
(In '000s)
(Unaudited)
Ìý

Three Months Ended June 30,

Ìý

Six Months Ended June 30,

2025

Ìý

2024 *

Ìý

2025

Ìý

2024 *

Recurring revenues
Financial Health

$

53,322

$

52,798

$

108,586

$

104,914

Patient Care

Ìý

28,115

Ìý

Ìý

27,135

Ìý

Ìý

55,562

Ìý

Ìý

55,678

Ìý

Total recurring revenues

Ìý

81,437

Ìý

Ìý

79,933

Ìý

Ìý

164,148

Ìý

Ìý

160,592

Ìý

Ìý
Non-recurring revenues
Financial Health

Ìý

962

Ìý

Ìý

1,711

Ìý

Ìý

1,831

Ìý

Ìý

3,034

Ìý

Patient Care

Ìý

3,330

Ìý

Ìý

3,956

Ìý

Ìý

6,958

Ìý

Ìý

6,091

Ìý

Total non-recurring revenues

Ìý

4,292

Ìý

Ìý

5,667

Ìý

Ìý

8,789

Ìý

Ìý

9,125

Ìý

Ìý
Total revenues

$

85,729

Ìý

$

85,600

Ìý

$

172,937

Ìý

$

169,717

Ìý

Ìý
*As described in the 2024 Annual Report, certain line items have been revised to correct an error related to the reversal of revenue from customers that was recognized improperly during 2023. These revisions increased revenue for the three and six months ended June 30, 2024 by $0.9 million and $1.7 million, respectively. These revisions had no cash flow consequences.

Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with accounting principles generally accepted in the United States of America, or “GAAP.� However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures that are prepared in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management uses these non-GAAP financial measures in order to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. In addition, management understands that some investors and financial analysts find these non-GAAP financial measures helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

We do not provide a reconciliation of the non-GAAP guidance measure Adjusted EBITDA for the second quarter of 2025 or the fiscal year 2025 to net income for such periods, the most comparable GAAP financial measure, due to the inherent difficulty of forecasting certain types of expenses and gains, without unreasonable effort, which affect net income but not Adjusted EBITDA.

As such, to supplement the GAAP information provided, we present in this press release and during the live webcast discussing our financial results the following non-GAAP financial measures: Adjusted EBITDA, Adjusted EBITDA Margin, Non-GAAP net income, and Non-GAAP earnings per share (“EPS�).

We calculate each of these non-GAAP financial measures as follows:

  • Adjusted EBITDA â€� Adjusted EBITDA consists of GAAP net income as reported and adjusts for (i) depreciation expense; (ii) amortization of software development costs; (iii) amortization of acquisition-related intangibles; (iv) stock-based compensation; (v) severance and other nonrecurring charges; (vi) interest expense and other income; (vii) gain on disposal of property and equipment; (viii) gain on sale of AHT; and (ix) the provision for (benefit from) income taxes.
  • Adjusted EBITDA Margin â€� Adjusted EBITDA Margin is calculated as Adjusted EBITDA, as defined above, divided by total revenue.
  • Non-GAAP net income â€� Non-GAAP net income consists of GAAP net income as reported and adjusts for (i) amortization of acquisition-related intangible assets; (ii) stock-based compensation; (iii) severance and other nonrecurring charges; (iv) non-cash interest expense; (v) gain on sale of AHT; and (vi) the total tax effect of items (i) through (v).
  • Non-GAAP EPS â€� Non-GAAP EPS consists of Non-GAAP net income, as defined above, divided by weighted average shares outstanding (diluted) in the applicable period.

Certain of the items excluded or adjusted to arrive at these non-GAAP financial measures are described below:

  • Amortization of acquisition-related intangibles â€� Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. We exclude acquisition-related amortization expense from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation, and the related amortization expense will recur in future periods.
  • Stock-based compensation â€� Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards. We exclude stock-based compensation expense from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of the timing and valuation of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods, and such expense will recur in future periods.
  • Severance and other nonrecurring charges â€� Non-recurring charges relate to certain severance and other charges incurred in connection with activities that are considered non-recurring. We exclude non-recurring expenses (primarily related to costs associated with our recent business transformation initiative and transaction-related costs) from non-GAAP financial measures because we believe (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods.
  • Non-cash Interest expense â€� Non-cash interest expense includes amortization of deferred debt issuance costs. We exclude non-cash interest expense from non-GAAP financial measures because we believe these non-cash amounts relate to specific transactions and, as such, may not directly correlate to the underlying performance of our business operations.
  • Interest expense and other income â€� Interest expense and other income represents (i) interest incurred on our term loan and revolving credit facility and (ii) non-cash interest expense. We exclude interest expense from non-GAAP financial measures because we believe these amounts relate to specific transactions and, as such, may not directly correlate to the underlying performance of our business operations.
  • Gain on disposal of property and equipment â€� Gain on disposal of property and equipment represents the excess of proceeds received over the book value of assets disposed of during the period. We exclude gain on disposal of property and equipment from non-GAAP financial measures because we believe (i) the amount of such gain or loss in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such gain or loss can vary significantly between periods.
  • Gain on sale of AHT â€� Gain on sale of AHT represents the excess of proceeds received over the net assets sold from our sale of AHT, our previously wholly-owned post-acute business, in January 2024. We exclude gain on sale of AHT from non-GAAP financial measures because we believe the amount relates to a specific transaction and, as such, may not directly correlate to the underlying performance of our business operations.
  • Tax shortfall (windfall) from stock-based compensation â€� ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, became effective for the Company during the third quarter of 2017 and changes the treatment of tax shortfall and excess tax benefits arising from stock based compensation arrangements. Prior to ASU 2016-09, these amounts were recorded as an increase (for excess benefits) or decrease (for shortfalls) to additional paid-in capital. With the adoption of ASU 2016-09, these amounts are now captured in the period’s income tax expense. We exclude this component of income tax expense from non-GAAP financial measures because we believe (i) the amount of such expenses or benefits in any specific period may not directly correlate to the underlying performance of our business operations; and (ii) such expenses or benefits can vary significantly between periods as a result of the valuation of grants of new stock-based awards, the timing of vesting of awards, and periodic movements in the fair value of our common stock.

Management considers these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends, in particular the extent to which ongoing operations impact our overall financial performance. In addition, management may use Adjusted EBITDA, Non-GAAP net income and/or Non-GAAP EPS to measure the achievement of performance objectives under the Company’s stock and cash incentive programs. Note, however, that these non-GAAP financial measures are performance measures only, and they do not provide any measure of cash flow or liquidity. Non-GAAP financial measures are not alternatives for measures of financial performance prepared in accordance with GAAP and may be different from similarly titled non-GAAP measures presented by other companies, limiting their usefulness as comparative measures. Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP. Additionally, there is no certainty that we will not incur expenses in the future that are similar to those excluded in the calculations of the non-GAAP financial measures presented in this press release. Investors and potential investors are encouraged to review the “Unaudited Reconciliation of Non-GAAP Financial Measures� above.

Investor Relations Contact

Asher Dewhurst, ICR Healthcare

[email protected]

Media Contact

Tracey Schroeder

Chief Marketing Officer

[email protected]

Source: TruBridge, Inc.

TruBridge Inc

NASDAQ:TBRG

TBRG Rankings

TBRG Latest News

TBRG Latest SEC Filings

TBRG Stock Data

313.84M
12.54M
16.52%
68.4%
5.37%
Health Information Services
Services-computer Programming Services
United States
MOBILE